Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.5023
+0.0021 (0.42%)
At close: Oct 23, 2026, 4:00 PM EDT
0.4900
-0.0123 (-2.45%)
After-hours: Oct 23, 2026, 7:39 PM EDT
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Oncolytics Biotech Inc.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Jared Kelly |
Contact Details
Address: 4350 Executive Drive, Suite 325 San Diego, California 92121 United States | |
| Phone | 403 670 7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001129928 |
| CUSIP Number | 68237V103 |
| ISIN Number | US68237V1035 |
| Employer ID | 98-0541667 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| John McAdory | Chief Operating Officer |
| Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Jon Patton | Director of Investor Relations and Communication |
| Yujun Wu | Vice President and Head of Biostatistics |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 6, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 10-Q | Quarterly Report |